Table 4. SIRs of second primary cancers in survivors of multiple myeloma (MM) by follow–up time after first MM in Germany and Sweden*.
| Sites of second cancers | Germany |
Sweden |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <1 yr |
1–4 yrs |
≥5 yrs |
<1 yr |
1–4 yrs |
≥5 yrs |
|||||||||||||
| N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | |
| Stomach | 9 | 0.9 | (0.4–1.6) | 21 | 1.0 | (0.6–1.6) | 11 | 1.7 | (0.9–3.1) | 1 | 0.5 | (0.0–2.8) | 7 | 1.9 | (0.8–3.9) | 0 | ||
| Colorectum | 18 | 0.5 | (0.3–0.7) | 60 | 0.8 | (0.6–1.0) | 26 | 1.1 | (0.7–1.6) | 13 | 1.0 | (0.5–1.8) | 38 | 1.6 | (1.1–2.1) | 6 | 0.9 | (0.3–1.9) |
| Liver and gallbladder | 5 | 0.8 | (0.3–1.8) | 14 | 1.1 | (0.6–1.8) | 4 | 0.9 | (0.3–2.4) | 2 | 1.8 | (0.2–6.5) | 3 | 1.6 | (0.3–4.6) | 1 | 0.9 | (0.0–5.2) |
| Lung | 24 | 0.8 | (0.5–1.3) | 41 | 0.7 | (0.5–1.0) | 19 | 1.1 | (0.6–1.7) | 7 | 1.6 | (0.6–3.3) | 9 | 1.1 | (0.5–2.1) | 6 | 1.3 | (0.5–2.9) |
| Breast | 7 | 0.3 | (0.1–0.6) | 49 | 1.0 | (0.7–1.3) | 13 | 0.8 | (0.4–1.3) | 5 | 0.8 | (0.2–1.8) | 19 | 1.2 | (0.7–1.9) | 6 | 1.3 | (0.5–2.8) |
| Endometrium | 5 | 0.9 | (0.3–2.2) | 3 | 0.3 | (0.1–0.8) | 0 | 0 | 3 | 1.4 | (0.3–4.1) | 2 | 1.2 | (0.1–4.2) | ||||
| Prostate | 37 | 0.9 | (0.6–1.2) | 55 | 0.6 | (0.5–0.8) | 25 | 0.9 | (0.6–1.3) | 22 | 1.2 | (0.8–1.8) | 28 | 1.1 | (0.7–1.6) | 15 | 1.6 | (0.9–2.6) |
| Kidney | 10 | 1.1 | (0.5–2.1) | 18 | 1.0 | (0.6–1.6) | 7 | 1.2 | (0.5–2.5) | 7 | 3.1 | (1.2–6.4) | 10 | 1.9 | (0.9–3.6) | 0 | ||
| Urinary bladder | 5 | 0.4 | (0.1–1.0) | 13 | 0.6 | (0.3–1.0) | 5 | 0.7 | (0.2–1.6) | 5 | 1.0 | (0.3–2.2) | 8 | 0.8 | (0.4–1.6) | 6 | 1.4 | (0.5–3.0) |
| Melanoma | 6 | 1.0 | (0.3–2.1) | 18 | 1.4 | (0.8–2.2) | 7 | 1.7 | (0.7–3.4) | 1 | 0.3 | (0.0–1.4) | 16 | 1.9 | (1.1–3.2) | 5 | 1.5 | (0.5–3.5) |
| Nervous system | 3 | 1.2 | (0.2–3.5) | 7 | 1.4 | (0.6–2.8) | 2 | 1.2 | (0.1–4.2) | 6 | 3.0 | (1.1–6.6) | 8 | 1.4 | (0.6–2.7) | 3 | 3.2 | (0.7–9.5) |
| Non–Hodgkin lymphoma | 11 | 1.5 | (0.8–2.8) | 8 | 0.6 | (0.2–1.1) | 3 | 0.7 | (0.1–1.9) | 1 | 0.4 | (0.0–2.0) | 13 | 2.2 | (1.2–3.7) | 2 | 1.3 | (0.2–4.5) |
| Leukemia | 8 | 1.4 | (0.6–2.8) | 18 | 1.6 | (1.0–2.6) | 9 | 2.5 | (1.2–4.8) | 7 | 1.7 | (0.7–3.5) | 13 | 1.8 | (1.0–3.1) | 4 | 1.1 | (0.3–2.9) |
| Myeloid leukemia | 6 | 2.7 | (1.0–5.8) | 16 | 3.7 | (2.1–5.9) | 9 | 6.3 | (2.9–12) | 2 | 1.4 | (0.2–5.0) | 9 | 2.3 | (1.0–4.3) | 3 | 1.8 | (0.4–5.2) |
| Acute myeloid leukemia | 4 | 3.0 | (0.8–7.7) | 13 | 5.0 | (2.7–8.6) | 7 | 8.2 | (3.3–17) | 2 | 1.9 | (0.2–6.8) | 8 | 2.7 | (1.2–5.4) | 3 | 2.0 | (0.4–5.8) |
| Chronic myeloid leukemia | 1 | 1.7 | (0.0–9.3) | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | ||||||
| Unknown primary | 5 | 1.0 | (0.3–2.4) | 9 | 0.9 | (0.4–1.8) | 2 | 0.6 | (0.1–2.3) | 2 | 0.9 | (0.1–3.1) | 7 | 1.7 | (0.7–3.6) | 1 | 6.1 | (0.2–34) |
| Total combineda | 198 | 0.8 | (0.7–1.0) | 402 | 0.9 | (0.8–1.0) | 152 | 1.0 | (0.8–1.2) | 88 | 1.1 | (0.9–1.4) | 199 | 1.4 | (1.2–1.6) | 62 | 1.3 | (1.0–1.7) |
Only cancers shown in Table 2 are presented.
*Rounding off for SIRs above 10; Bold type (elevated risk) and underscored type (decreased risk): 95% CIs did not include 1.00.
aIncluding cancers not presented individually.